Viatris Acquires Pacira for $1.65 Billion to Build Non-Opioid Pain Portfolio
Viatris agreed to acquire Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion, adding two marketed
Read moreDetails
Sign Up For Our Newsletter
Subscribe to our mailing list to receives daily updates direct to your inbox!
Latest News
Regeneron’s Claims Ledger: What Management Said, What the Filings Show, and What October 30 Will Settle
Regeneron spent most of 2024 and 2025 telling investors a story about transition: EYLEA, its aging eye-injection blockbuster, was losing...
Caribou Biosciences halts CAR-T programs and explores sale as financing dries up
Caribou Biosciences announced it is evaluating strategic alternatives, including a merger or sale, and will discontinue development of its
Regeneron secures $1 billion upfront and profit-share deal with Sanofi on four new antibodies
Regeneron and Sanofi have expanded their 17-year collaboration to co-develop and co-commercialize four new long-acting antibodies targeting
Bargains & Bubbles
The Economy
29,000 Jobs and 3.4% Inflation: Two Numbers That Cannot Both Be Right
For most of the past two years, the Federal...
Growth and Prices Are Both Holding Up. That Shouldn’t Be Possible.
The quick read The third estimate for Q2 2026,...
Prices at the Factory Gate Are Running Hot. Wages Are Not. Something Has to Give.
Five years ago, the word "transitory" was the most...
From Bargains & Bubbles
Viatris: The Stock Has Run 72% in a Year. The Filed Numbers Tell a More Complicated Story.
The share price is up 72% over the past twelve...
From The Economy
29,000 Jobs and 3.4% Inflation: Two Numbers That Cannot Both Be Right
For most of the past two years, the Federal Reserve's...
Latest News
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.